Abpro Corporation, a biotechnology company developing next-generation antibody therapies for severe and life-threatening diseases, has announced a term sheet to enter into a definitive business combination with Atlantic Coastal Acquisition Corp. II, a special purpose acquisition corporation. The deal, which was signed on September 18, 2023, is expected to close in the second quarter of…